Sascha Troschke-Meurer

13PUBLICATIONS
34CO-AUTHORS
Radiation therapyGene and molecular therapyHaematological tumoursBiological network analysisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 13, 2025
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Holger N Lode, Przemysław Holko, Aleksandra Wieczorek

|Aug 14, 2025
Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.

Sascha Troschke-Meurer, Maxi Zumpe, Peter Moritz Ahrenberg

|Jul 08, 2025
Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Holger N Lode, Nikolai Siebert, Dominique Valteau-Couanet

|Jan 08, 2025
XModNN: Explainable Modular Neural Network to Identify Clinical Parameters and Disease Biomarkers in Transcriptomic Datasets.

Jan Oldenburg, Jonas Wagner, Sascha Troschke-Meurer

|Jul 14, 2023
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.

Holger N Lode, Ruth Ladenstein, Sascha Troschke-Meurer

|Jul 14, 2023
Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.

Nikolai Siebert, Maxi Zumpe, Christian Heinrich Schwencke

Pageof 3

Frequent Collaborators

10 joint publications

Holger N Lode

8 joint publications

Nikolai Siebert

7 joint publications

Maxi Zumpe

3 joint publications

Madlen Marx